Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis

Hepatitis C virus (HCV) can be eliminated by direct-acting antivirals in patients with decompensated liver cirrhosis. Although viral clearance in decompensated liver cirrhosis leads to improvement of the liver function and quality of life, changes in the skeletal muscle mass after sustained virologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakamori, Ryotaro, Yamada, Ryoko, Shinkai, Kazuma, Doi, Akira, Tahata, Yuki, Shigekawa, Minoru, Kodama, Takahiro, Hikita, Hayato, Yamada, Tomomi, Tatsumi, Tomohide, Takehara, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990635/
https://www.ncbi.nlm.nih.gov/pubmed/33642562
http://dx.doi.org/10.2169/internalmedicine.6029-20
Descripción
Sumario:Hepatitis C virus (HCV) can be eliminated by direct-acting antivirals in patients with decompensated liver cirrhosis. Although viral clearance in decompensated liver cirrhosis leads to improvement of the liver function and quality of life, changes in the skeletal muscle mass after sustained virologic response (SVR) in patients with decompensated liver cirrhosis have not been reported. We present the first report of skeletal muscle mass improvement with the achievement of SVR for HCV in a 76-year-old woman with decompensated liver cirrhosis. After achieving SVR through ledipasvir/sofosbuvir treatment, the patient showed an improvement in her liver function and an increase in her skeletal muscle mass.

Ejemplares similares